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Scale Plus the Type of Onset Can Predict Survival Rates
and the Duration of Immunosuppressive Therapy
Jose A. Perez-Simon, Cristina Encinas, Fernando Silva, Maria Jose Arcos, Marıa Dıez-
Campelo, Fermın M. Sanchez-Guijo, Enrique Colado, Jesus Martın, Lourdes Vazquez,
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Several grading systems have been developed in the bone marrow transplantation setting in attempts to pre-
dict survival in patients with chronic graft-versus-host disease (cGVHD). In this study, we evaluated the prog-
nostic value of the National Institutes of Health (NIH) scoring system and investigated for any additional
prognostic factors in a series of 171 patients undergoing peripheral blood stem cell transplantation (PBSCT)
from matched related donors. The cumulative incidence of cGVHD was 70%; cumulative incidences of mild,
moderate, and severe cGVHDwere 29%, 42% and 28%, respectively. Overall, 68% of patients were free from
immunosuppression 5 years after transplantation. Absence of previous acute GVHD (aGVHD; hazard ratio
[HR] 5 2; P 5 .004) and mild cGVHD (HR 5 4.2; P 5 .007) increased the probability of being off immuno-
suppressive treatment by the last follow-up. Overall survival (OS) at 5 years was 52%. Severe cGVHD,
according to the NIH scoring system (HR 5 13.27; P 5 .001) adversely influenced outcome, whereas de
novo onset (HR5 0.094; P 5 .003) had a more favorable impact on survival. The combination of both vari-
ables allowed us to identify 4 different subgroups of patients withOS of 82%, 70%, 50%, and 25%.Our findings
indicate that the NIH scoring system has some prognostic value in patients undergoing PBSCTand, together
with the type of onset, must be considered to predict the possible outcome of patients who develop cGVHD.
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Chronic graft-versus-host disease (cGVHD) is
a major complication after allogeneic hematopoietic
stem cell transplantation (HSCT) that impairs quality
of life and functional status and adversely affects
long-term survival [1-4]. Historically, cGVHD has
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doi:10.1016/j.bbmt.2008.07.015been classified as ‘‘limited’’ or ‘‘extensive’’ on the basis
of the results of a small retrospective study [5]. This
classification system was developed primarily to distin-
guish patients requiring systemic immunosuppression
from those for whom local care might suffice. Never-
theless, most patients experience extensive-stage
cGVHD.This constitutes an extremely heterogeneous
population.Furthermore,althoughsuchaclassification
system can be easily used in many centers [6], it fails to
stratify patients according to outcome. For this reason,
several grading systems have been developed to predict
survival and late treatment-relatedmortality in patients
diagnosedwith cGVHD.Along these lines, Akpek et al.
[7] developed a prognosticmodel based on the presence
of extensive skin involvement, thrombocytopenia,
and progressive-type onset in a series of patients
undergoing allogeneic bone marrow transplantation
(BMT). According to theKarnofky performance score,1163
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have been identified as prognostic factors in a large reg-
istry-based analysis of patients receiving BMT almost
exclusively [8].
Table 1. Characteristics of the patients at transplantation
(n 5171)
Tr Tr
Age, years, median (range) 45 (14 to 69)
Diagnosis
AML, n 44
ALL, n 24
MM, n 21
NHL, n 20
MDS, n 19
CML, n 14
CLL, n 10
HD, n 9
MPD, n 6
Aplasia, n 2
Others, n 2
Disease status at transplantation*
Low risk, n (%) 63 (37%)
Intermediate risk, n (%) 75 (43%)
High risk, n (%) 33 (20%)
Sex†
Male, n 100
Female, n 71
Conditioning regimen
Myeloablative, n 68
Reduced-intensity conditioning, n 103
Charlson comorbidity index
Low, n 113
Intermediate low, n 37
Intermediate high, n 10
High, n 11
CD34 infused  106/kg, median (range) 5.1 (1.9 to 13.2)
*Low risk: first complete remission or chronic phase; high risk: relapse
or progressive disease, blast crisis; intermediate risk: all others.
†A total of 39 male patients received PBSCT from a female donor.More recently, the National Institutes of Health
(NIH) Consensus Development Project proposed
a new clinical scoring system for the global assessment
of cGVHD severity based on the number of organs in-
volved and the degree of functional impairment in af-
fected organs (mild, moderate, or severe). This allows
the identification of patients requiring a purely topical
approach or no immunosuppression, and also facili-
tates decision making regarding the timing and inten-
sity of therapy. Nevertheless, this scoring system
requires validation with a large series of patients to
demonstrate its prognostic impact [9].
Previous studies have identified the risk factors
for cGVHD after HSCT, including previous acute
GVHD (aGVHD), advanced age, use of female donors
for male recipients, and use of unrelated or HLA-mis-
matched donors [10,11]. Compared with BMT, in pe-
ripheral blood stem cell transplantation (PBSCT), the
incidence of cGVHD is higher [12], and patients re-
quire more successive treatments to achieve control
[13], leading to a longer duration of immunsuppressive
therapy. Accordingly, the prognostic models of
cGVHD in the BMT setting may not necessarily apply
to patients undergoing PBSCT. With regard to this,
Pavletic et al. [14] reported that a platelet count \
100  109/L and a history of aGVHD point to
a poor outcome in patients undergoing PBSCT who
develop cGVHD.
In this current study, we evaluated the prognostic
impact of the new clinical scoring system proposed
by the NIH Consensus Development Project and in-
vestigated for additional prognostic factors in a series
of patients undergoing PBSCT from amatched related
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Figure 1. Cumulative incidence of cGVHD according to standard criteria (A) and to NIH-based criteria (B).
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Patient Characteristics
A total of 171 patients consecutively undergoing
non–T cell–depleted PBSCT at our institution be-
tween January 1998 and March 2007 were included
in the analysis. Patients receiving a bonemarrow trans-
plantation, an allogeneic transplant from an unrelated
donor, or GVHD prophylaxis other than cyclosporin
(CsA) and methotrexate (MTX) were not included in
the analysis. Patients were retrospectively categorized
according to the NIH scoring system based on the
data obtained from the medical history, which speci-
fied organ involvement and graded according to the
Table 2. Actuarial incidence of cGVHD and organ in-
volvement (patients with > 100 days of follow-up; n 5 150)
CGVHD
Yes 91
No 59
Type of cGVHD
Limited 22
Extensive 69
Severity of cGVHD
Mild 24
Moderate 42
Severe 25
Type of onset
De novo 45
Quiescent 38
Progressive 8
Organ involvement
Skin
Mild 38
Moderate 9
Severe 5
Mouth
Mild 58
Moderate 4
Severe
Eyes
Mild 35
Moderate 3
Severe 1
Gut
Mild 17
Moderate 9
Severe 2
Liver
Mild 33
Moderate 7
Severe 7
Lung
Mild 5
Moderate 9
Severe 1
Kidney
Mild 1
Moderate 1
Severe
Muscle/joints
Mild 3
Moderate 2
Severe
Counts at the time of cGVHD diagnosis
Platelets: Median (range)  106/L 179 (18 to 482)
Eosinophils: Median (range)  106/L 198 (0 to 3.550)
cGVHD indicates chronic graft-versus-host disease.classical limited vs extensive classification. The patient
characteristics are summarized in Table 1.
Myeloablative conditioning consisted of cyclo-
phosphamide (Cy) 60 mg/kg 2 days intravenously
and fractionated total body irradiation (TBI; total 12
Gy) or busulfan (Bu) 1 mg/kg 4 times daily over 4
days. Patients receiving reduced-intensity condition-
ing (RIC) were treated with fludarabine (Flu) 30 mg/
m2/day on days -9 to -5, followed by either busulfan
(Bu) 1 mg/kg every 6 hours on days -6 and -5 and 1
mg/kg every 12 hours on day -4 or melphalan 70 mg/
m2/day on days -3 and -2 in patients diagnosed with
myelogenous or lymphoid malignancies, respectively.
GVHD Prophylaxis and Treatment
For GVHD prophylaxis, patients received CsA 0.5
mg/kg every 12 hours from day -7 to -2 and 1.5 mg/kg
every 12 hours from day –1, plus MTX 15 mg/m2/day
on day -1 and 10mg/m2 on days13,16, and111, fol-
lowed by folinic acid rescue. CsA taper was started on
approximately day 150 and stopped on day 1180 if
GVHD did not flare. A faster taper could have been
scheduled, had active disease or minimal residual dis-
ease been detected. Tacrolimus was used instead of
CsA to avoid CsA-related toxicity.
The first-line treatment for aGVHD was based on
the administration of 6-methyl-prednisonole 2 mg/kg/
day in the event that grade $ 2 aGVHD developed.
Second-line treatment was administered if there was
progression at day 13, no response at day 17, and
no complete remission at day 114 after the beginning
of the treatment.
The first-line treatment for extensive cGVHDwas
based on CsA or tacrolimus plus prednisone at 1 mg/
kg/day, which was switched to alternating days after
4 weeks of treatment. The disease response was evalu-
ated 5 weeks after the introduction of steroids and ev-
ery 3 months thereafter until the end of treatment. All
patients received antibacterial, antifungal, and antiviral
prophylaxis according to standard protocols [15].
Definitions
Based on to the NIH scoring system [9], mild
cGVHD was diagnosed when only 1 or 2 organs or
sites (except the lung; see below) were involved, with
no clinically significant functional impairment (maxi-
mum score of 1 in all affected organs or sites). Moder-
ate cGVHD involved at least 1 organ or site with
clinically significant impairment but no major disabil-
ity (maximum score of 2 in any affected organ or site)
or 3 or more organs or sites with no clinically signifi-
cant functional impairment (maximum score of 1 in
all affected organs or sites). A lung score of 1 also
was considered moderate cGVHD. Severe cGVHD
was defined as a major disability caused by cGVHD
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Figure 2. Relapse of cGVHD in patients who responded to first-line treatment (A) and according to the NIH scale (B).(score of 3 in any organ or site). A lung score of$ 2 also
was considered severe cGVHD.
Patients who were receiving prednisone or were
still receiving a therapeutic dose of CsA to treat previ-
ous aGVHD that had evolved into cGVHD without
the resolution of symptoms were considered to have
‘‘progressive’’ cGVHD. Patients who were on CsA ta-
per with resolution of symptoms or who were free
from immunosuppression at the time of diagnosis
were categorized as ‘‘quiescent,’’ whereas those with
no previous history of aGVHD were classified as hav-
ing ‘‘de novo’’ cGVHD. Otherwise, aGVHD and lim-
ited GVHD versus extensive cGVHD were graded
based on established criteria [5].
Statistical Analysis
Mean and median values along with 95% confi-
dence intervals (CI) and ranges were calculated for
each continuous variable. The Student t test and Pear-
son’s c2 test were used to compare continuous and
qualitative variables. In comparisons in which the
number of cases precluded the use of parametric tests,
the Mann-Whitney test and Fisher’s exact tests for 2
2 tables were used. All P values for these tests are re-
ported as 2-tailed P values.
The events analyzed were calculated from the time
of transplantation using Kaplan-Meier product-limit
estimates. Treatment-related mortality (TRM) was
defined as death due to causes unrelated to the under-
lying disease, and relapsing patients were censored at
the time of relapse. GVHD-related mortality was de-
fined as death due to causes directly related to
GVHD. Deaths attributed to immunosuppression in
patients requiring treatment for GVHD also were
considered GVHD-related mortalities. Event-free
survival (EFS) was calculated from the time of trans-plantation until disease progression or death. Patients
who did not achieve disease response (complete remis-
sion [CR] or partial response [PR]) at any time after
transplantation were considered events on day 100,
because this was the first date of complete disease
evaluation. Overall survival (OS) was calculated from
transplantation until death from any cause, and surviv-
ing patients were censored at the last follow-up.
Patients who demonstrated evidence of engraft-
ment were evaluable for aGVHD, whereas patients
who engrafted and survived for more than 100 days
were evaluable for cGVHD. The contraction of
aGVHD or cGVHD was calculated from the time of
transplantation until diagnosis of aGVHD or cGVHD
in an evaluable patient. The cumulative incidence esti-
mates for GVHD were performed taking into account
death as a competing risk. To calculate the percentage
of patients receiving immunosuppressive therapy at
any time after transplantation, only those patients at
risk at that specific time point were included in the
analysis. All of the factors that significantly or margin-
ally (P\ .10) influenced the incidence or outcome of
cGVHD in the univariate analysis were included in
multivariate analysis using a forward-step Cox regres-
sion model.
SPSS version 10 (SPSS Inc, Chicago, IL) was used
for most of the statistical analyses. Computations and
testing of cumulative incidences were performed with
the cmprsk package R 1.9.1. Differences were consid-
ered statistically significant at a P value\ .05.
RESULTS
GVHD Incidence and Characteristics
The cumulative incidence of aGVHD was 40%
for grade II-IV and 10% for grade III-IV. cGVHD
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(range, 90 to 1150 days). The cumulative incidence
of cGVHD was 70% in patients surviving . 100
days after transplantation, with 60% classified with ex-
tensive cGVHD. The cumulative incidences of mild,
moderate, and severe cGVHD were 29%, 42%, and
28%, respectively (Figure 1). Among the 69 patients
diagnosed with extensive cGVHD, 6 had mild
cGVHD, 39 had moderate cGVHD, and 24 had se-
vere cGVHD. Organ involvement in the 6 patients
with extensive cGVHD (retrospectively classified as
mild GVHD) included involvement of the skin and
gut (n 5 1), liver and gut (n 5 1), kidney (n 5 1),
gut (n5 1), and liver and mouth (n5 2). In all of these
cases, the severity of organ involvement was consid-
Table 3. Factors associated with response or relapse to im-
munosuppressive treatment
Response to
treatment
CR plus
PR/CR
Actuarial
incidence (%)
Univariate
P value
HR
(95% CI)
Multivariate
P value
Grade of cGVHD .4
Mild 95/68
Moderate 92/60
Severe 82/41
Type of onset .04
De novo 90/67
Quiescent 90/53
Progressive 60/20
Relapse to
immunosuppressive
treatment among
responders
Cumulative
incidence
Patient sex .05
Male 70%
Female 47%
Grade of cGVHD .05
Mild 26% 12.5 (2.6 to 60) .002
Moderate 70% 20.9 (2.3 to 183) .006
Severe 80%
cGVHD .07
limited 38%
extensive 74%
Performance status .03
ECOG < 2 54%
ECOG $ 2 82%
Ocular involvement .002
No 63%
Grade 1 76%
Grade 2 to 3 100%
Gut involvement < .001
No 60%
Grade 1 70%
Grade 2 96%
Grade 3 100%
Liver involvement .011
No 59%
Grade 1 64%
Grade 2 80%
Grade 3 100%
Lung involvement .007
No 65%
Grade 1 60%
Grade 2 100%ered mild. Table 2 summarizes the incidences of
cGVHD and organ involvement.
Response to Immunosuppressive Treatment
and Relapse of GVHD
To evaluate the response to or relapse after immu-
nosuppressive therapy, only patients who received
first-line treatment (ie, patients diagnosed with exten-
sive cGVHD) were evaluated. Overall, 90% of patients
reached at least PR after first-line treatment, with 58%
achieving CR. Only the type of onset significantly
influenced the probability of responding to treatment;
the CR rate was 67% in patients with cGVHD, 53% in
those with quiescent cGVHD, and 20% in those with
progressive cGVHD.
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Figure 3. Probability of being off immunosuppression at last follow-up.
Table 4. Variables associated with immunosuppression
withdrawal
Off
immunosuppression
at last follow-up*
Cumulative
incidence
Univariate
P value
HR
(95% CI)
Multivariate
P value
Age .081
<p50 81%
>p50 47%
Prior aGVHD .04
Yes 72%
No 49% 2.7 (1.3 to 6) .004
Grade of cGVHD < .001
Mild 71% 4.2 (1.4 to 12.12) .007
Moderate 58%
Severe 57%
Onset .02
De novo 71%
Quiescent 56%
Progressive 13%
Performance status .015
ECOG < 2 66%
ECOG $ 2 44%
Ocular involvement .015
No 73%
Grade 1 50%
Grade 2 0%
Grade 3 0%
*Univariate and multivariate analysis included those patients requiring
systemic immunosuppression any time after transplantation.
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who responded to initial treatment was 61%
(Figure 2A). Table 3 summarizes the variables that
had a significant influence on relapse after first-line
treatment. In multivariate analysis, only the severity
of cGVHD according to the NIH scoring system sig-
nificantly influenced the risk of relapse (hazard ratio
[HR] 5 12.5; 95% confidence interval [CI] 5 2.6-60;
P 5 .002 for moderate cGVHD and HR 5 20.9;
95% CI 5 2.3-183; P 5 .006 for severe cGVHD)
(Figure 2B).
Table 5. GVHD-related mortality and survival
cGVHD-related
mortality
Cumulative
incidence
Univariate
P value
HR
(95% CI)
Multivariate
P value
Age .02
< p75 (55 years) 5%
> p75 (55 years) 23%
cGVHD .24
Limited 0%
Extensive 13%
Type of onset .004
De novo 3%
Quiescent 12%
Progressive 38%
Grade of severity .004
Mild 0%
Moderate 9%
Severe 30%
Performance status < .001
ECOG < 2 4%
ECOG $ 2 30%
Lung involvement < .001
No 5%
Mild 20%
Moderate 24%
Severe 100%
Liver involvement .008
No 3%
Mild 11%
Moderate 15%
Severe 38%
OS 5-year OS
cGVHD .04
Limited 87%
Extensive 64%
Grade of cGVHD < .001
Mild 83% 13.27 (2.81 to 62.5) .001
Moderate 77%
Severe 46%
Type of onset .03
De novo 77% 0.094 (0.02 to 0.43) .003
Quiescent 64%
Progressive 57%
Performance status < .001
ECOG < 2 79%
ECOG $ 2 47%
Liver involvement < .001
No 85%
Grade 1 76%
Grade 2 63%
Grade 3 28%
Lung involvement < .001
No 80%
Grade 1 71%
Grade 2 66%
Grade 3 0%Overall, 68% of patients were free from immuno-
suppressive treatment 5 years after transplantation
(Figure 3). Table 4 presents the variables that influ-
enced the probability of being free from immunosup-
pression by the last follow-up. According to
multivariate analysis, the absence of previous aGVHD
(HR 5 2.7; 95% CI 5 1.3-6; P 5 .004) and mild
cGVHD (HR 5 4.2; 95% CI 5 1.4-12.12; P 5 .007)
significantly increased the probability of being off im-
munosuppressive treatment by the last follow-up.
cGVHD-Related Mortality and Outcome
TRM was 19% by 5 years for the entire series of
patients and 12% for those patients surviving for
more than 100 days after transplantation. In this latter
subset of patients, cGVHD-related mortality was
10%. Causes of cGVHD-related death included fun-
gal and/or bacterial infection in 9 patients, respiratory
failure related to cGVHD in 4 patients, and both in
1 patient. Table 5 summarizes the variables that
significantly affected cGVHD-related mortality. In-
terestingly, no significant differences were observed
between patients diagnosed with limited cGVHD
and those with extensive cGVHD (0% vs 13%; P 5
.24), whereas both the NIH scoring system and
the type of onset significantly affected cGVHD-
related mortality. In terms of organ involvement, the
severity of liver and lung involvement, as well as per-
formance status, significantly influenced the mortality
of cGVHD-relapsed cases.
At 5 years, OS was 52% and event-free survival
(EFS) was 48%. Table 5 also summarizes the variables
that significantly influenced OS. In multivariate analy-
sis, severe cGVHD adversely influenced outcome (HR
5 13.27; 95% CI 5 2.81-62.5; P 5 .001), whereas de
novo onset had a more favorable impact on survival
(HR 5 0.094; 95% CI 5 0.02-0.43; P 5 .003)
(Figure 4).
Interestingly, patients categorized as mild
cGVHD had similar survival regards of the type of
onset, ranging from 80% to 87% at 5 years. In con-
trast, in patients with moderate cGVHD, de novo on-
set allowed us to differentiate a subgroup of patients
with more favorable outcome, similar to those diag-
nosed with mild cGVHD (82% at 5 years) and signif-
icantly better than those with quiescent or progressive
onset (70% at 5 years). Finally, within the severe
cGVHD subgroup, de novo onset versus moderate
or severe cGVHD also allowed us to differentiate 2
subgroups in terms of survival (50% OS at 5 years
for patients with de novo vs 25% OS at 5 years for
those with quiescent or progressive onset). Thus, the
combination of both variables allowed us to identify
different subgroups of patients in terms of outcome
(Figure 5).
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Figure 4. OS and EFS for the whole series of patients (A); OS in patients with de novo, quiescent, or progressive-onset cGVHD (B); and OS in patients
with mild, moderate, or severe cGVHD (C).To evaluate which severity grade had a greater im-
pact on outcome, we carried out a multivariate analysis
excluding the overall severity grade according to the
NIH scale. In this analysis, performance status \ 2
(HR 5 0.26; 95% CI 5 0.1-0.62; P 5 .003) and liver
involvement 5 3 (HR 5 14.3; 95% CI 5 3.4-60.32;
P\ .001) significantly affected the outcome.
DISCUSSION
Several models have been developed to identify the
clinical and biological features with prognostic signif-
icance in patients who develop cGVHD [7,8]. Most
previous studies have been conducted in patients un-
dergoing BMT, not taking into account the fact that
characteristics of cGVHD differ between PBSCT
and BMT. With regard to this, PBSCT is associated
with a higher incidence of cGVHD compared with
BMT [12]. Furthermore, the number of successive
lines of treatment needed to control cGVHD is higher
after PBSCT, meaning that these patients require
a longer duration of immunosuppressive therapy
[13,16]. In this regard, Pavletic et al. [14] have reported
that some prognostic factors may be unique to recipi-
ents of PBSCT and do not apply to those undergoing
BMT. Accordingly, in the PBSCT setting, specific
models are needed to establish different prognostic
subgroups to allow identification of patients who can
be treated with topical or mild immunosuppression,
in contrast to those requiring a more aggressive ap-
proach. This is especially pertinent because although
cGVHD can lead to severe complications adversely
affecting quality of life and survival, it also is related
to a graft-versus-leukemia effect, which significantly
decreases the risk of relapse after allogeneic transplan-
tation [15,17-19]. Accordingly, the development of
accurate models with prognostic significance in the
PBSCT setting will help individualize therapeutic
strategies.TheNIH has proposed a new scoring system to es-
tablish standard criteria for the diagnosis of cGVHD
[9]. This system attempts to do this by describing the
extent and severity of cGVHDfor each organ or site in-
volved at any given time. In doing so, it seeks to estab-
lish new guidelines for the global assessment of
cGVHDand to propose indications for topical and sys-
temic therapies. Nevertheless, this scoring system re-
quires validation to define the prognostic impact of
the subgroups that it identifies as mild, moderate, and
severe cGVHD. In the current study, we confirmed
that most of the patients who developed cGVHD
were classified as having extensive cGVHD, with only
a minority having limited cGVHD according to the
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Figure 5. OS in patients with cGVHD according to NIH score plus
type of onset. OS, depending on grade of severity according to the
NIH scoring system plus type of onset, was 82% for patients with mild
cGVHD regardless of the type of onset and patients with moderate
cGVHD with de novo onset, 70% for patients with moderate cGVHD
and quiescent or progressive onset, 50% for patients with severe
cGVHD and de novo onset, and 25% for patients with severe cGVHD
and quiescent or progressive onset.
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system, because all 3 categories had a similar number
of patients, thus allowing better stratification of the
patients for both therapeutic and prognostic purposes.
In addition, some of the patients diagnosed with ex-
tensive cGVHD were retrospectively classified as
having mild cGVHD. Based on the superior outcome
of this small subset of patients, it can be speculated
that they could have benefited from avoiding systemic
immunosuppression, as suggested by the NIH scoring
system.
Concerning cGVHD-related mortality, a good
performance status at the time of cGVHD diagnosis,
according to the NIH scoring system and the type of
onset, significantly influenced the outcome in univari-
ate analysis. Regarding specific organs, the severity of
liver and lung involvement significantly influenced
the outcome of patients who developed cGVHD.
These variables have been identified as independent
prognostic factors in previous studies [16]. In contrast,
we did not identify platelet count as a prognostic fac-
tor, which may be explained by the high median num-
ber of platelets (79  109/L) found at the time of
cGVHD diagnosis [7,8,14]. The same variables also
influenced OS in univariate analysis, whereas in multi-
variate analysis, both the type of onset and NIH scor-
ing significantly affected outcome. In this regard, de
novo onset of GVHD was associated with a favorable
prognosis, whereas severe cGVHD had an adverse im-
pact on survival. Based on multivariate analysis, we de-
veloped a scoring system that considers both type of
onset and grade of severity, which allowed us to differ-
entiate 4 subgroups that clearly differed in terms of
outcome, with OS of 82%, 70%, 50%, and 25%.
Previous studies have shown that 30% to 70% of
patients surviving beyond 100 days after transplanta-
tion require immunosuppressive treatment for more
than 2 years [1,16,20]. In the current study, we con-
firmed, in a series of homogeneously treated patients
undergoing PBSCT, that the NIH scoring system, be-
sides its impact on outcome, is the most important
prognostic factor in predicting the risk of relapse after
first-line cGVHD treatment. When considered along
with previous development of aGVHD, this system al-
lows us to identify those patients receiving immuno-
suppressive therapy at the last follow-up. In this
regard, patients with mild cGVHD had a significantly
higher probability of being free from immunosuppres-
sive therapy at last follow-up compared with those
with moderate or severe cGVHD.
In conclusion, the NIH scoring system is of prog-
nostic value in patients undergoing PBSCT and, to-
gether with the type of onset, must be considered to
predict the outcome of patients who develop cGVHD.
These parameters should be taken into account to
adapt immunosuppressive strategies and decrease the
risk to patients.ACKNOWLEDGMENTS
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